To summarize the clinical and imaging features, treatment, and prognosis of leucine-rich glioma-inactivated protein 1 (LGI1) antibody-positive limbic encephalitis. Methods：In this paper, 1 case of LGI1 antibody-positive limbic encephalitis treated in our hospital was reported, and the relevant literature was reviewed. Results：The patient was a 60-year-old female who presented with progressive memory loss, seizures (including generalized tonic-clonic seizure and faciobrachial dystonic seizure), hyponatremia, and mild mental and behavioral abnormalities. The brain MRI-T2/Flair sequence showed abnormally high signal intensity in the medial temporal lobe and hippocampus on both sides of the temporal lobe (especially the left). The cerebrospinal fluid was positive for anti-LGI1 antibody (++ ). After corticosteroids treatment, the patient’s symptoms improved. We collected data of 237 cases of LGI1 antibody-positive limbic encephalitis from PubMed. Most patients showed acute and sub-acute onset, and the most common symptoms were memory impairment, epilepsy (including facial-brachial dystonia), and hyponatremia. Cerebral MRI (especially the MRI-T2/FLAIR sequence) in most patients showed abnormalities in the unilateral or bilateral hippocampal and temporal lobes. Prognosis was improved when immunotherapy was initiated at an early stage. Conclusion: LGI1 antibody-positive limbic encephalitis has unique clinical characteristics, and immunotherapy can significantly improve prognosis.